{
    "eid": "2-s2.0-84906242695",
    "title": "Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy",
    "cover-date": "2014-01-01",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [
        "Asian",
        "Metastatic renal cell carcinoma",
        "Sunitinib"
    ],
    "authors": [
        "Se Hoon Lee"
    ],
    "citedby-count": 39,
    "ref-count": 23,
    "ref-list": [
        "SU11248 inhibits KIT and platelet-derived growth factor receptor \u03b2 in preclinical models of human small cell lung cancer",
        "In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship",
        "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo",
        "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma",
        "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma",
        "[Clinical study of Sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience].",
        "Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma",
        "Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial",
        "Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma",
        "Sunitinib in patients with metastatic renal cell carcinoma",
        "New guidelines to evaluate the response to treatment in solid tumors",
        "Predictors of body surface area",
        "Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma",
        "Targeted therapy and handfoot skin reaction in advanced renal cell carcinoma",
        "The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: High incidence of toxicity leads to frequent dose reduction",
        "Genetic determinants of cancer drug efficacy and toxicity: Practical considerations and perspectives",
        "A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients",
        "A Phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: Insights into the treatment, efficacy and safety",
        "Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100",
        "J Clin Oncol",
        "Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity",
        "J Clin Oncol",
        "Ann Oncol"
    ],
    "affiliation": [
        {
            "affiliation-city": "Seoul",
            "affilname": "Yonsei Cancer Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taoyuan",
            "affilname": "Chang Gung University College of Medicine",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Quezon City",
            "affilname": "St. Luke's Medical Center Quezon City",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Hong Kong",
            "affilname": "Queen Mary Hospital Hong Kong",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Singapore City",
            "affilname": "National Cancer Centre, Singapore",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Brisbane",
            "affilname": "Mater Hospital Brisbane",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Seoul",
            "affilname": "Seoul National University Hospital",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "affilname": "University of Malaya Medical Centre",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "New York",
            "affilname": "Pfizer Oncology",
            "affiliation-country": "United States"
        }
    ],
    "funding": []
}